Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data

[1]  V. Preedy,et al.  Scottish Intercollegiate Guidelines Network , 2010 .

[2]  J. Cramer,et al.  Potentially Inappropriate Antiepileptic Drugs for Elderly Patients with Epilepsy , 2004, Journal of the American Geriatrics Society.

[3]  R. Verbeeck,et al.  Effect of age and sex on the plasma binding of acidic and basic drugs , 2004, European Journal of Clinical Pharmacology.

[4]  L. Eberly,et al.  Antiepileptic drug use in nursing home admissions , 2003, Annals of neurology.

[5]  E. Perucca,et al.  Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs , 2003, The Lancet Neurology.

[6]  L. Wilkins.  Variability of total phenytoin serum concentrations within elderly nursing home residents , 2003, Neurology.

[7]  A. Birnbaum,et al.  Variability of total phenytoin serum concentrations within elderly nursing home residents , 2003, Neurology.

[8]  M. Morrell,et al.  The Expert Consensus Guideline Series Treatment of Epilepsy , 2001, Epilepsy & Behavior.

[9]  M. A. Marx,et al.  Correlation and Prediction of Phenytoin Protein Binding Using Standard Laboratory Parameters in Patients After Renal Transplantation , 2001, Therapeutic drug monitoring.

[10]  S. Shorvon,et al.  Harnessing the Clinical Potential of Antiepileptic Drug Therapy , 2001, CNS drugs.

[11]  L. Willmore,et al.  Choice and Use of Newer Anticonvulsant Drugs in Older Patients , 2000, Drugs & aging.

[12]  C. Gross,et al.  Factors associated with antiepileptic drug use among elderly nursing home residents. , 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.

[13]  M. Brodie,et al.  Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy , 1999, Epilepsy Research.

[14]  K. Bachmann,et al.  Differential Kinetics of Phenytoin in Elderly Patients , 1999, Drugs & aging.

[15]  F. Abbott,et al.  Chemistry and biotransformation , 1999 .

[16]  R. Chaponis,et al.  An Evaluation of Antiepileptic Drug Therapy In Nursing Facilities , 1998, Journal of the American Geriatrics Society.

[17]  Tanaka.  In vivo age‐related changes in hepatic drug‐oxidizing capacity in humans , 1998, Journal of clinical pharmacy and therapeutics.

[18]  R. Vestal,et al.  Pharmacokinetic Optimisation of Drug Therapy in Elderly Patients , 1995, Drugs & aging.

[19]  M. Giroud,et al.  Early Seizures After Acute Stroke: A Study of 1,640 Cases , 1994, Epilepsia.

[20]  P. Chand,et al.  Pharmacokinetics of phenytoin in routine clinic patients in Malaysia * , 1994, Journal of clinical pharmacy and therapeutics.

[21]  I. Leppik,et al.  Antiepileptics in the elderly. Pharmacoepidemiology and pharmacokinetics. , 1994, Archives of family medicine.

[22]  M. Lancman,et al.  Risk Factors for Developing Seizures After a Stroke , 1993, Epilepsia.

[23]  I. Saavedra,et al.  [Phenytoin pharmacokinetics in young and older adults]. , 1992, Revista medica de Chile.

[24]  A. Dasgupta,et al.  Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis. Role of uremic compounds. , 1992, American journal of clinical pathology.

[25]  R. Tallis,et al.  How common are epileptic seizures in old age? , 1991, Age and ageing.

[26]  B. K. Park,et al.  Aging and drug interactions. II. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. , 1988, The Journal of pharmacology and experimental therapeutics.

[27]  T. Tomson.  Choreoathetosis induced by ordinary phenytoin levels, explained by high free fraction?--A case report. , 1988, Therapeutic drug monitoring.

[28]  N. Buchanan,et al.  Identifying Patients Who Might Benefit from Free Phenytoin Monitoring , 1987, Therapeutic drug monitoring.

[29]  P. Blain,et al.  Steady-state Pharmacokinetics of Phenytoin from Routinely Collected Patient Data , 1983, Clinical pharmacokinetics.

[30]  G. Peterson,et al.  Plasma protein binding of phenytoin in 100 epileptic patients. , 1982, British journal of clinical pharmacology.

[31]  L A Bauer,et al.  Age and phenytoin kinetics in adult epileptics , 1982, Clinical pharmacology and therapeutics.

[32]  M. Eadie,et al.  Plasma protein binding of phenytoin in the aged: in vivo studies. , 1982, British journal of clinical pharmacology.

[33]  L. Skovsted,et al.  Disposition of Antipyrine and Phenytoin Correlated with Age and Liver Volume in Man , 1981, Clinical pharmacokinetics.

[34]  E. Perucca.  Plasma protein binding of phenytoin in health and disease: relevance to therapeutic drug monitoring. , 1980, Therapeutic drug monitoring.

[35]  A. Richens,et al.  A Study of the Pharmacokinetics of Phenytoin (Diphenylhydantoin) in Epileptic Patients, and the Development of a Nomogram for Making Dose Increments , 1975, Epilepsia.

[36]  A. Richens,et al.  Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients. , 1975, British journal of clinical pharmacology.

[37]  M. J. Hayes,et al.  Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding. , 1975, British journal of clinical pharmacology.

[38]  H. Booker,et al.  Concurrent administration of phenobarbital and diphenylhydantoin , 1971, Neurology.